Artimplant expands its long-term degradable Artelon® Surgical Suture product range

Artelon® Surgical Suture, available in USP sizes 2-0, 0, 1 and 2, with and without needle has been cleared for marketing in the USA.

CEO Tord Lendau about the new clearance; “Our Artelon® Surgical Suture fulfils specific unmet clinical needs in a market where there currently are no suitable sutures. It is a long-term degradable suture with unique biocompatibility and superior knotability that offers new therapeutic advantages in high demand clinical situations such as patients with slowly healing tissue. Due to the variety of indications in which the Artelon® Surgical Suture is suitable, we plan to market the product through non-exclusive distribution agreements with major medical technology companies.” Longer degradation time Artelon® Surgical Suture has a significantly longer degradation time compared to absorbable sutures currently on the market. In high demand clinical situations such as patients with slowly healing tissue or tissue exposed to high mechanical load, surgeons often use non-absorbable sutures, since the current absorbable sutures degrade too rapidly. These non-absorbable sutures frequently need to be removed at a second surgery. In situations like these, Artelon®’s unique properties offer new therapeutic advantages. Superior knotability Artelon® Surgical Suture has both superior knotability and knot security, meaning that they are easily tied and require fewer knots to obtain secure locking. Clinicians have particularly stressed the importance of these features in arthroscopic suturing. Also, due to the elasticity of Artelon®, they behave similarly to their host tissue and thereby reduce the risk of tearing. Unique biomaterial Artelon® is a unique long term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue – Artelon® offers new solutions to unmet clinical needs in several therapy areas. For additional information, please contact: Tord Lendau, CEO, phone +46 (0)31 746 56 00, +46 (0)708 369 403, tord.lendau@artimplant.se Web site: www.artimplant.com About Artimplant Artimplant’s mission is to develop, produce and market implants based on the biomaterial Artelon® that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas. Artimplant’s vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.